Alvarez & Marsal Announces 2025 Managing Director Promotions
16.1.2025 17:36:00 CET | Business Wire | Press release
Leading global professional services firm Alvarez & Marsal (A&M) has announced the promotion of 80 professionals, across Brazil, Canada, France, Germany, India, Italy, Spain, Sweden, United Arab Emirates, United Kingdom, and the United States, to the position of Managing Director.
Tony Alvarez II and Bryan Marsal, A&M’s Co-Founders, stated, “All of our newly promoted Managing Directors embody the talent and leadership necessary to deliver exceptional results that create value for A&M’s clients. Their contributions to the growth of our firm and the clients we serve cannot be understated. From around the world and across our many lines of service, they exemplify A&M’s unwavering commitment to integrity, quality and objectivity, and are essential to the firm’s continued success and expansion.”
- Russell Hunt, Houston
- Jack Kobus, Detroit
- Long Nguyen, Washington, D.C.
- Luis De Lencquesaing, New York
- Christopher Disa, New York
- Phani Mogalapu,Houston
Corporate Performance Improvement
- Kindra Bradshaw, Washington, D.C.
- Clark Caperton, Houston
- Rodrigo Carrillo, Houston
- Jeffrey Cass, Houston
- Trey Huffman, Atlanta
- Rob Koczo,Dallas
- Haley Leyendecker, Denver
- Andrew Monaco, Dallas
- Dan Phillips, Atlanta
- Brenden Phillips-Garrett, Los Angeles
- Eduardo Areilza, Madrid
- Massimo Franzese, London
- Tom Howitt, Abu Dhabi
- Hardeep Sandhu, London
- Florian Seehauser, Munich
- Jonas Strasdas, Munich
Private Equity Performance Improvement
- Colleen McCaughan, London
- Nick Mountfield, London
- Daniela Torresin, Milan
- Dario Bortot,London
- John Costoudes, Dubai
- Elizaveta Malashenko, Houston
Global Disputes and Investigations
- Jon Ahern, Denver
- Brad Koehler, New York
- John Bettley-Smith, London
- Daniella Divito,New York
- Emily Edwards, Atlanta
- Orion Ganase,London
- Alon Kritzman, New York
- Bruce Meyer, San Francisco
- Michael Noreman, Morristown
- Axel Ortjohann, Frankfurt
- Rob Piechota, Atlanta
- Chris Prout, London
Global Transaction Advisory Group
- Mike Baxter,Toronto
- Erminio Caporale, Chicago
- Kevin Cunha,San Francisco
- Ryan Donovan,Boston
- Vivian Leemans,Düsseldorf
- Kate Lowry,New York
- Ryan Macke, Chicago
- Callum Moore, Stockholm
- Gaurav Patel,Toronto
- Alex Rankin, Dubai
- Simon Regad,Paris
- Paul Spencer, London
- Michael Surr,New York
- Austin Wanland, Los Angeles
- Sujith Jain, Bangalore
Infrastructure & Capital Projects
- Felipe Bergson, Rio de Janeiro
- Bryan Müller, Belo Horizonte
- Alexandre Aguieiras, Rio de Janeiro
- Janice Garay, São Paulo
- Guilherme Kam, São Paulo
- Patrick Lopes, São Paulo
- Eduardo Teixeira, São Paulo
North American Commercial Restructuring
- Dwight Hingtgen,Chicago
- Landon Kenworthy,Dallas
- Paul Kinealy,Chicago
- Kumanan Ramanathan, New York
- Mauricio Rivera,San Francisco
- John Walsh,Houston
Private Equity Performance Improvement
- Alexander Galitsky,Chicago
- Vincent Juron,Charlotte
- Jason Kahn,Philadelphia
- Jeff Liddle, Houston
- Ahmed Suria,Philadelphia
- Ben Taylor,Atlanta
- Shiwali Tenner,Chicago
- Hameer Vaid,New York
- Christopher Baglio, Chicago
- Tracey Esposito, New York
- Roger Wilcock, London
About Alvarez & Marsal
Founded in 1983, Alvarez & Marsal is a leading global professional services firm. Renowned for its leadership, action and results, Alvarez & Marsal provides advisory, business performance improvement and turnaround management services, delivering practical solutions to address clients' unique challenges. With a world-wide network of experienced operators, world-class consultants, former regulators and industry authorities, Alvarez & Marsal helps corporates, boards, private equity firms, law firms and government agencies drive transformation, mitigate risk and unlock value at every stage of growth.
To learn more, visit: AlvarezandMarsal.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250114027719/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom